| Name | Title | Contact Details |
|---|
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.
Great Lakes Health Plan, Inc. is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The employees of SynergEyes are committed to provide the highest quality, technologically advanced hybrid contact lenses that address a wide spectrum of vision conditions, while continuously meeting the needs of today's Practitioner and Patient.
Carrot is a complete global fertility solution for today`s modern employers and payers, providing flexible financial coverage and expert care navigation across the U.S. and 50+ countries. Get a quick demo and briefing about how modern companies are using Carrot to drive down healthcare costs, attract and retain top talent, and build cultures of inclusion.